Because targeting CCR2 or monocytes is a proposed strategy for targeted therapy in cancer, steatohepatitis, traumatic brain injury, Alzheimer’s disease, and multiple sclerosis (43, –, 48), our work suggests that targeting this pathway might offer clinical benefits to patients with inflammatory CNS disease. Here, CCR2 is linked to early-onset autosomal dominant Alzheimer disease.